MedTrace Logo

A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

NCT00002399 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and effectiveness of SCH 56592 with that of fluconazole in the treatment of OPC (a fungal infection of the throat) in HIV-positive patients.

Conditions

  • Candidiasis, Oral
  • HIV Infections

Interventions

DRUG

Posaconazole

DRUG

Fluconazole

Sponsors & Collaborators

  • Schering-Plough

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Argentina
  • Belgium
  • Canada
  • Chile
  • Dominican Republic
  • Ethiopia
  • France
  • Germany
  • Guatemala
  • Honduras
  • Israel
  • Mexico
  • Panama
  • South Africa
  • Spain
  • Thailand
  • Venezuela

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002399 on ClinicalTrials.gov